|
|
||||||||
The Squibb Institute for Medical Research, New Brunswick, New Jersey
Correspondence: For reprints contact: A. D. Nunn, The Squibb Institute for Medical Research, P.O. Box 191, New Brunswick, NJ 08903-0191.
ABSTRACT
Technetium-99m-CDO-MeB ((Bis[1,2-cyclohexanedione- dioximato(1-)-O]-[1,2-cyclohexanedione dioximato(2)-O]methyl-borato(2-)- N,N',N'',N''',N'''',N''''')-chlorotechnetium) belongs to a family of compounds generally known as boronic acid adducts of technetium dioxime complexes (BATOs). It has an intrinsic affinity for the myocardium, with negligible lung activity and rapid blood clearance. The uptake of 3.44 %ID in rat heart at 1 min postinjection for [99mTc]CDO-MeB versus 3.03% for 201Tl indicates high extraction of [99mTc]CDO-MeB by the myocardium. In dogs an ischemic defect is clearly seen in SPECT images obtained 10 min after injection of [99mTc]CDO-MeB. Tissue distribution data in rats show that [99mTc]CDO-MeB is excreted primarily in the feces and to a lesser extent in the urine. Approximately 80% of the activity is excreted within 24 hr after injection.
This article has been cited by other articles:
![]() |
K. Hatada, L. M. Riou, M. Ruiz, Y. Yamamichi, A. Duatti, R. L. Lima, A. R. Goode, D. D. Watson, G. A. Beller, and D. K. Glover 99mTc-N-DBODC5, a New Myocardial Perfusion Imaging Agent with Rapid Liver Clearance: Comparison with 99mTc-Sestamibi and 99mTc-Tetrofosmin in Rats J. Nucl. Med., December 1, 2004; 45(12): 2095 - 2101. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |